Eli Lilly and Company (LLY) - Total Assets
Based on the latest financial reports, Eli Lilly and Company (LLY) holds total assets worth $142.28 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Eli Lilly and Company - Total Assets Trend (1985–2025)
This chart illustrates how Eli Lilly and Company's total assets have evolved over time, based on quarterly financial data. Also see market value of Eli Lilly and Company for the company's overall valuation and market capitalisation.
Eli Lilly and Company - Asset Composition Analysis
Current Asset Composition (December 2025)
Eli Lilly and Company's total assets of $142.28 Billion consist of 49.5% current assets and 50.5% non-current assets. Review LLY total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $7.27 Billion | 6.4% |
| Accounts Receivable | $20.16 Billion | 17.9% |
| Inventory | $13.74 Billion | 12.2% |
| Property, Plant & Equipment | $25.93 Billion | 23.1% |
| Intangible Assets | $6.52 Billion | 5.8% |
| Goodwill | $5.90 Billion | 5.2% |
Asset Composition Trend (1985–2025)
This chart illustrates how Eli Lilly and Company's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Eli Lilly and Company stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eli Lilly and Company's current assets represent 49.5% of total assets in 2025, an increase from 49.1% in 1985.
- Cash Position: Cash and equivalents constituted 6.4% of total assets in 2025, down from 10.3% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 2.0% in 1985.
- Asset Diversification: The largest asset category is property, plant & equipment at 23.1% of total assets.
Eli Lilly and Company Competitors by Total Assets
Key competitors of Eli Lilly and Company based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pfizer Inc
NYSE:PFE
|
USA | $201.13 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $136.46 Billion |
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.80 Billion |
|
AstraZeneca PLC
MX:AZNN
|
Mexico | MX$114.07 Billion |
|
Novartis AG ADR
NYSE:NVS
|
USA | $122.03 Billion |
|
AstraZeneca PLC
F:ZEGA
|
Germany | €114.46 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$201.13 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $32.09 Billion |
Eli Lilly and Company - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.35 | 1.28 | 1.30 |
| Quick Ratio | 1.00 | 1.00 | 1.02 |
| Cash Ratio | 0.00 | 0.09 | 0.28 |
| Working Capital | $16.93 Billion | $10.83 Billion | $4.13 Billion |
Eli Lilly and Company - Advanced Valuation Insights
This section examines the relationship between Eli Lilly and Company's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 31.20 |
| Latest Market Cap to Assets Ratio | 9.14 |
| Asset Growth Rate (YoY) | 42.9% |
| Total Assets | $112.48 Billion |
| Market Capitalization | $1.03 Trillion USD |
Valuation Analysis
Premium Asset Valuation: The market values Eli Lilly and Company's assets at a significant premium (9.14x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Eli Lilly and Company's assets grew by 42.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Eli Lilly and Company (1985–2025)
The table below shows the annual total assets of Eli Lilly and Company from 1985 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $112.48 Billion | +42.89% |
| 2024-12-31 | $78.71 Billion | +22.98% |
| 2023-12-31 | $64.01 Billion | +29.33% |
| 2022-12-31 | $49.49 Billion | +1.40% |
| 2021-12-31 | $48.81 Billion | +4.66% |
| 2020-12-31 | $46.63 Billion | +18.70% |
| 2019-12-31 | $39.29 Billion | -10.53% |
| 2018-12-31 | $43.91 Billion | -2.38% |
| 2017-12-31 | $44.98 Billion | +15.91% |
| 2016-12-31 | $38.81 Billion | +9.10% |
| 2015-12-31 | $35.57 Billion | -2.03% |
| 2014-12-31 | $36.31 Billion | +3.00% |
| 2013-12-31 | $35.25 Billion | +2.47% |
| 2012-12-31 | $34.40 Billion | +2.20% |
| 2011-12-31 | $33.66 Billion | +8.58% |
| 2010-12-31 | $31.00 Billion | +12.89% |
| 2009-12-31 | $27.46 Billion | -6.00% |
| 2008-12-31 | $29.21 Billion | +9.05% |
| 2007-12-31 | $26.79 Billion | +22.01% |
| 2006-12-31 | $21.96 Billion | -10.68% |
| 2005-12-31 | $24.58 Billion | -1.15% |
| 2004-12-31 | $24.87 Billion | +14.71% |
| 2003-12-31 | $21.68 Billion | +13.84% |
| 2002-12-31 | $19.04 Billion | +15.87% |
| 2001-12-31 | $16.43 Billion | +11.87% |
| 2000-12-31 | $14.69 Billion | +14.55% |
| 1999-12-31 | $12.83 Billion | +1.82% |
| 1998-12-31 | $12.60 Billion | +0.14% |
| 1997-12-31 | $12.58 Billion | -12.09% |
| 1996-12-31 | $14.31 Billion | -0.73% |
| 1995-12-31 | $14.41 Billion | -0.65% |
| 1994-12-31 | $14.51 Billion | +50.75% |
| 1993-12-31 | $9.62 Billion | +10.96% |
| 1992-12-31 | $8.67 Billion | +4.51% |
| 1991-12-31 | $8.30 Billion | +16.18% |
| 1990-12-31 | $7.14 Billion | +22.14% |
| 1989-12-31 | $5.85 Billion | +11.12% |
| 1988-12-31 | $5.26 Billion | +0.15% |
| 1987-12-31 | $5.25 Billion | +14.34% |
| 1986-12-31 | $4.60 Billion | +16.24% |
| 1985-12-31 | $3.95 Billion | -- |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 7… Read more